Image Sourced ShutterStock
The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Healthia has entered binding agreements to acquire nine more health clinics around Australia
  • The clinics include: three physiotherapy in Queensland and six podiatry clinics in Queensland and Victoria
  • The nine new health clinics will cost Healthia $5.620 million

Healthia Limited has entered binding agreements to acquire nine more health clinics around Australia.

The health clinics include: three physiotherapy clinics in Queensland, three podiatry clinics in Queensland and three podiatry clinics in Victoria.

Healthia is an integrated group of health-based companies, who aim to help people in health services. Healthia has allied businesses such as My FoorDr, Allsports Physiotherapy, Extend Rehabilitation, iOrthotics and D.B.S. Medical Supplies.

Financial and property leases will have to be approved and settlement is expected to be by August 31.

These nine new health clinics will cost Healthia $5.620 million and are expected to bring in $6.717 million.

CEO, Wes Coote is happy with the acquisitions of the new health clinics and is excited for what the rest of the year holds.

“We are pleased with the partnership we have been able to make with new clinics throughout FY19 and happy with the momentum we are gaining moving into FY20,” he said.

HLA by the numbers
More From The Market Herald

The Calmer Co locks in $700k in funding via convertible note issue

The Calmer Co (ASX:CCO) has confirmed its receipt of $700,000 in funding from existing shareholders.

FDA greenlights Botanix Pharmaceuticals’ Sofdra resubmission plan

FDA approves Botanix's strategy for Sofdra NDA resubmission with no additional materials requested, keeping submission to…

Botanix Pharmaceuticals successfully closes $13.5m Placement to boost US commercial activities

Botanix Pharmaceuticals (ASX: BOT) has closed its $13.5 million placement to both new and existing institutional…

Pharmaust completes Phase One Monepantel study and files for Orphan Drug Designation

Pharmaust (ASX:PAA) has announced that all patients have completed its phase one MEND study using monepantel…